Declan Bennett

Declan Bennett

Auto-generated profile, based on publicly available information

Declan Bennett

Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell Reports
Verified
Journal Article
Open access
MRMichael D. Rainey
Michael D. Rainey
DBDeclan Bennett
Declan Bennett
RORachel O’dEa
Rachel O’dEa
MZMelania Eva Zanchetta
Melania Eva Zanchetta
MVMuriel Voisin
Muriel Voisin
CSCorrado Santocanale
Corrado Santocanale
DNA replication initiates from multiple origins, and selective CDC7 kinase inhibitors (CDC7is) restrain cell proliferation by limiting origin firing. We have performed a CRISPR-Cas9 genome-wide screen to identify genes that, when lost, promote the proliferation of cells treated with sub-efficacious doses of a CDC7i. We have found that the loss of function of ETAA1, an ATR activator, and RIF1 reduce the sensitivity to CDC7is by allowing DNA synthesis to occur more efficiently, notably during late S phase. We show that partial CDC7 inhibition induces ATR mainly through ETAA1, and that if ATR is subsequently inhibited, origin firing is unleashed in a CDK- and CDC7-dependent manner. Cells are then driven into a premature and highly defective mitosis, a phenotype that can be recapitulated by ETAA1 and TOPBP1 co-depletion. This work defines how ATR mediates the effects of CDC7 inhibition, establishing the framework to understand how the origin firing checkpoint functions.

15 December 2025 in Nature Communications
Verified
Journal Article
Open access
Charlie C. WrightCharlie C. Wright
Charlie C. Wright
MPMin Pan
Min Pan
GPGregory A. Phelps
Gregory A. Phelps
JLJonathan Low
Jonathan Low
DCDuane Currier
Duane Currier
PGPaul Geeleher
Paul Geeleher
Drug combinations are essential to modern medicine, but their discovery remains slow and inefficient as experimental complexity expands rapidly with each additional drug tested. Although modern liquid handling systems enable complex and highly customizable experimental designs, a lack of strategies integrating these technologies with combination-specific analytical methods has limited throughput. Here we introduce Combocat, an open-source and streamlined framework that combines acoustic liquid handling protocols with machine learning-based inference to achieve ultrahigh-throughput drug combination screening. Using Combocat, we generate a reference dataset of over 800 unique combinations in a dense 10 × 10 matrix format across multiple cell types, and use this to train a predictive model that accurately infers drug combination effects from sparse data, drastically reducing the number of experimental measurements required. As proof of concept, we screened 9,045 combinations in a neuroblastoma cell line-the largest number of combinations tested in a single cell line to date-achieved using minimal resources. By integrating advanced drug dispensing technologies with predictive computational modeling, Combocat provides a scalable solution to accelerate the discovery of novel drug combinations.

5 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DBD Bennett
D Bennett
MWM Wierdl
M Wierdl
SCS Chakraborty
S Chakraborty
JJJd Johnson
Jd Johnson
VAV Akingbehin
V Akingbehin
SZS Zhang
S Zhang
Alternative lengthening of telomeres (ALT) is a telomerase-independent pathway used by aggressive cancers to maintain their replicative immortality. Because ALT is absent from normal human cells, it is an appealing target for cancer therapy, but the lack of ability to determine ALT status at scale has hindered discovery. Here, we developed ALTitude, a machine learning method from a tabular foundation model that infers ALT from cell line whole genome sequencing data, without need for paired germline analysis. We deployed ALTitude across the DepMap, doubling the number of known ALT+ cancer models. Systematic integration of ALTitude with CRISPR-Cas9 screens yielded the selective dependency on SMARCAL1 in ALT+ cell lines, where we show it stabilizes the ALT phenotype. Acute depletion of SMARCAL1 leads to G2/M arrest, mitotic catastrophe, and cell death. These data provide a valuable resource for studying ALT-related genomic features and present SMARCAL1 as a therapeutic target for ALT+ malignancies.

22 April 2026 in Cancer Research
Verified
Journal Article
Open access
JFJake D. Friske
Jake D. Friske
FCFlore Cuisin
Flore Cuisin
PGPaloma Guernalec
Paloma Guernalec
HMHayden A. Malone
Hayden A. Malone
SNStephanie Nance
Stephanie Nance
MRMartine F. Roussel
Martine F. Roussel
MYC is amplified on extrachromosomal DNA (ecDNA) or homogeneously staining regions (HSR) in group 3 medulloblastoma (G3-MB), conferring a poor prognosis. A better understanding of the mechanisms underlying MYC expression in ecDNA and HSRs could be leveraged to develop improved treatments for G3-MB. Using a structure–function approach, we identified and characterized an enhancer (ecMYC E1) that drives MYC activation specifically in G3-MB with MYC-amplified ecDNA or HSRs. The ecMYC E1 locus exhibited enhancer hallmarks exclusively in MYC-amplified G3-MB but not in other MYC-dependent cancer cell lines, including those with MYC amplification. Silencing of the ecMYC E1 enhancer significantly reduced MYC transcription, which was compensated for by increases in ecDNA copy number. Neuronal differentiation 1 and bromodomain-containing protein 4 interacted with each other and bound to ecMYC E1, looping the enhancer to the MYC promoter. Together, these findings define a mechanism that regulates amplified MYC gene expression within ecDNA or HSRs specifically in G3-MB. Significance: Combined structural and functional approaches identified a conserved enhancer activating MYC transcription exclusively in MYC-amplified ecDNA- and HSR-positive group 3 medulloblastoma, providing a potential therapeutic target for suppressing MYC.

22 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDeclan Bennett
Declan Bennett
DODonal O’shea
Donal O’shea
JFJohn Ferguson
John Ferguson
Derek MorrisDerek Morris
Derek Morris
CSCathal Seoighe
Cathal Seoighe
Ongoing increases in the size of human genotype and phenotype collections offer the promise of improved understanding of the genetics of complex diseases. In addition to the biological insights that can be gained from the nature of the variants that contribute to the genetic component of complex trait variability, these data bring forward the prospect of predicting complex traits and the risk of complex genetic diseases from genotype data. Here we show that advances in phenotype prediction can be applied to improve the power of genome-wide association studies. We demonstrate a simple and efficient method to model genetic background effects using polygenic scores derived from SNPs that are not on the same chromosome as the target SNP. Using simulated and real data we found that this can result in a substantial increase in the number of variants passing genome-wide significance thresholds. This increase in power to detect trait-associated variants also translates into an increase in the accuracy with which the resulting polygenic score predicts the phenotype from genotype data. Our results suggest that advances in methods for phenotype prediction can be exploited to improve the control of background genetic effects, leading to more accurate GWAS results and further improvements in phenotype prediction.

4 July 2025 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
TMTyler D Medina
Tyler D Medina
DBDeclan Bennett
Declan Bennett
CSCathal Seoighe
Cathal Seoighe
Oxidative damage can introduce G>T mutations upon DNA replication. When this damage occurs ex vivo, sequenced DNA exhibits strand asymmetry, whereby sequence alignment yields G>T mismatches without corresponding C>A mismatches on the complementary strand at a given locus. Strand asymmetry is used to identify potential sequencing artefacts in somatic variant calls in cancer sequencing projects. Consistent with previous studies, we found that the strandedness of this asymmetry is frequently shared across targeted capture regions. However, while some exome sequencing datasets displayed consistent asymmetry relative to the forward reference strand, some surprisingly showed asymmetry relative to the transcription strand. Though oxidation is the principle cause of artefactual G>T mutations, we propose that the asymmetry stems from the use of single-stranded exome capture probes, as we did not find consistent asymmetry in matched whole genome sequencing. We further propose that high levels of asymmetry can be indicative of oxidation artefacts in the reported somatic variant calls of some samples. While most analysed cohorts showed low to moderate asymmetry, in one cohort (testicular germ cell tumour), approximately half of the reported G>T somatic mutations were likely to be oxidative damage artefacts, as indicated by the extent of asymmetry in mismatches and variants.